Researchers develop less toxic anti-cancer drug
New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.
A team of National University of Singapore (NUS) pharmacists and chemists has developed a new anti-cancer drug that has less toxic effects to the kidneys.
The new drug works like a ‘magic bullet’ that is delivered directly to the mitochondria — the power generators of cells — of cancer cells. Once the drug reaches the tumour, two active molecules — an anti-cancer drug and a sensitizer — are released at once, and they attack the mitochondria, leading to the death of cancer cells. Such a targeted approach reduces the drug’s interactions with other tissues, minimising side effects and it is expected to lower the risk of patients developing resistance to anti-cancer drugs like cisplatin.
“When designing and evaluating new cancer treatments, researchers often use cisplatin as a gold standard to compare new medicines. Cisplatin is known to kill cancer cells by damaging DNA. But cancer cells are smart, and they have ways to repair this damage and become resistant to the drug treatment. Hence, we need good alternatives that can address drug resistance and the associated side effects,” explained Associate Professor Ang Wee Han from NUS Chemistry.
He worked together with Associate Professor Giorgia Pastorin from NUS Pharmacy to look into developing an anti-cancer drug with better treatment outcomes to serve as an alternative to cisplatin. The research was conducted in collaboration with Professor Dan Gibson from The Hebrew University of Jerusalem.
Tumour disappears after targeted delivery of new drug
Recognising that the mitochondria have less efficient repair mechanisms in their DNA, the NUS team came up with a novel drug that can be delivered directly to them. This was achieved by adding a mitochondria-targeting ligand to the original cisplatin scaffold. This additional ligand has a strong positive charge that displays high affinity towards the complementary negative charge of the mitochondrial membrane.
The NUS researchers examined how their drug was released into the blood, and came up with a method to encapsulate their novel drug formulation in miniaturised drug carriers known as liposomal nanovesicles. As tumours grow very rapidly, their blood vessels do not have time to develop properly and they are leaky. Such an environment enables the permeation of the drug carriers from blood vessels to the tumour microenvironment, and be retained within the tumour to carry out the ‘attack’ on cancer cells.
Experiments by the researchers showed that the new drug, when delivered in a colon cancer model, shrank the tumour until it became impalpable.
“No sign of kidney inflammation was detected, unlike the use of conventional cisplatin. These results indicate that our invention is a viable alternative to cisplatin,” said Dr Maria Babak, who was the first author of the study.
“While our results show great potential, we want to further challenge ourselves to improve our drug so that we can achieve complete tumour remission and tackle drug resistance. Accomplishing such a feat will open doors to improving cancer treatment and survival rates,” said Assoc Prof Pastorin.
To improve the efficacy of the new drug, the research team is looking into adjusting the doses and frequencies of the treatment. They are also studying combinations of different anti-cancer drugs, and examining ways to packaging them into suitable drug delivery systems to increase efficacy, decrease side effects and tackle drug resistance among cancer patients.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance